In this study, we continued with the modifications of [6]-shogaol (4) to improve inhibitor enzyme binding and aimed to determine whether these compounds would be potent HDAC inhibitors and manifest antiproliferative activities against cancer cells, as well as maintaining their low toxicity. This evidence concerns the gene HDAC9 and cancer.